奥施康定联合岩舒注射液治疗中重度肺癌疼痛的临床观察
|
摘要
目的:探讨奥施康定联合岩舒注射液治疗中重度肺癌疼痛的临床疗效。方法:肺癌中重度疼痛患者98例,按照随机数字的方法分为对照组和观察组,每组49例患者,对照组患者使用奥施康定进行治疗,观察组患者在对照组治疗方法基础上使用岩舒注射液,对治疗的效果进行对比。结果:观察组患者完成治疗之后的疼痛缓解情况优于对照组患者,数据差异具有统计学意义(z=2. 879,P <0. 05),观察组患者的奥施康定使用量低于对照组患者,而且随着治疗时间延长,奥施康定使用量逐渐降低,数据差异具有统计学意义(P <0. 05),两组患者的平均镇痛起效时间,平均镇痛时间与平均滴定达到稳态时间数据差异均不具有统计学意义(P> 0. 05),观察组患者生活质量提高幅度高于对照组患者,观察组患者的各项不良反应发生率均低于对照组患者,数据差异均具有统计学意义(P <0. 05)。结论:利用奥施康定联合岩舒注射液治疗中重度肺癌疼痛的患者,可以提高疼痛缓解率,改善患者的生活质量,减少奥施康定使用量和不良反应发生率,值得在临床范围内进行推广。
Objective:To investigate the clinical effect of Oxycontin and Yanshu Injection on moderate-severe lung cancer pain. Methods: 98 severe lung cancer patients,according to the random number method were divided into control group and observation group,49 patients in each group. Patients in the control group were treated with Oxycontin. Patients in the observation group were treated with Yanshu Injection on the basis of the control group,and the treatment effect was compared. Result: Patients in the observation group had better pain relief after completing the treatment than those in the control group,and the difference was statistically significant( z = 2. 879,P < 0. 05). Oxycontin in observation group was lower than that in control group. With the prolongation of treatment time,the dosage of Oxycontin decreased gradually and the difference was statistically significant( P < 0. 05). There was no significant difference between the two groups in the mean time to onset of analgesia,the mean time to analgesia or the mean time to steady-state data(P > 0. 05). The quality of life of the observation group increased more than that of the control group. The incidence ofadverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant( P < 0. 05). Conclusion: Oxycodin combined with Yanshu Injection for patients with moderate to severe lung cancer pain can improve the pain relief rate and improve the quality of life of patients and reduce the amount of oxycodone and the incidence of adverse reactions,it is worthy of clinical promotion.
Objective:To investigate the clinical effect of Oxycontin and Yanshu Injection on moderate-severe lung cancer pain. Methods: 98 severe lung cancer patients,according to the random number method were divided into control group and observation group,49 patients in each group. Patients in the control group were treated with Oxycontin. Patients in the observation group were treated with Yanshu Injection on the basis of the control group,and the treatment effect was compared. Result: Patients in the observation group had better pain relief after completing the treatment than those in the control group,and the difference was statistically significant( z = 2. 879,P < 0. 05). Oxycontin in observation group was lower than that in control group. With the prolongation of treatment time,the dosage of Oxycontin decreased gradually and the difference was statistically significant( P < 0. 05). There was no significant difference between the two groups in the mean time to onset of analgesia,the mean time to analgesia or the mean time to steady-state data(P > 0. 05). The quality of life of the observation group increased more than that of the control group. The incidence ofadverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant( P < 0. 05). Conclusion: Oxycodin combined with Yanshu Injection for patients with moderate to severe lung cancer pain can improve the pain relief rate and improve the quality of life of patients and reduce the amount of oxycodone and the incidence of adverse reactions,it is worthy of clinical promotion.
引文
[1]李光,刘洪霞,刘军,等.不同化疗方案治疗复合性小细胞肺癌的效果和安全性比较[J].中国医药,2017,12(1):50-54.
[2]陈勇,黄红霞.加巴喷丁联合盐酸羟考酮缓释片对癌性神经痛患者疼痛介质的影响[J].中国实用神经疾病杂志,2017,20(4):116-118.
[3]胥秀,冯丹,贾罄竹,等.心智觉知干预模式对肺癌化疗患者生活质量和心理状况的影响[J].中华肺部疾病杂志(电子版),2017,10(1):50-54.
[4]张璐,朱敏,张慧,等. GCH1基因多态性与肺癌中晚期病人癌痛程度的相关性研究[J].中国疼痛医学杂志,2017,23(9):662-667.
[5]区妙兴,冼海兵,李巧云,等.医护合作式的电话随访在晚期肺癌患者疼痛管理中的应用[J].国际护理学杂志,2017,36(2):258-260.
[6]刘永叶,齐泽华,杨晓丹,等.奥施康定联合复方苦参注射液治疗胃癌晚期癌痛疗效观察[J].临床军医杂志,2017,45(1):13-15.
[7]郭一萌,杨静,严虹霞,等.复方苦参注射液辅助治疗肺癌的系统评价[J].中国医院用药评价与分析,2017,17(3):379-384.
[8]何静,李君,冯艺,等.利兹神经病理性症状和体征评分与疼痛强度的关系[J].中国疼痛医学杂志,2017,23(1):39-43.
[9]徐象威,朱佩祯,吕向群,等.临床药师参与大剂量阿片类药物癌痛会诊对患者疼痛及不良反应的分析[J].浙江医学,2017,39(3):208-211.
[10]胡夕春,王杰军,常建华,等.癌症疼痛诊疗上海专家共识(2017年版)[J].中国癌症杂志,2017,27(4):312-319.
[11]邓芸,卓兴峰,彭娟娟,等.盐酸羟考酮缓释片联合生物电刺激对神经病理性癌痛的治疗效果[J].川北医学院学报,2017,32(1):30-32.
[12]徐忠良,张辉,王德征,等. 2015年天津市户籍居民恶性肿瘤死亡及去死因期望寿命分析[J].中华流行病学杂志,2017,38(2):231-234.
[13]高崇荣.关于疼痛定义的商榷[J].中国疼痛医学杂志,2017,23(1):23-24.
[14]纪英,王倩,宋萍,等.自我效能干预对恶性肿瘤放化疗患者癌痛及生活质量的护理效果[J].中国医药导报,2017,14(8):171-174.
[15]唐丹,曾淑英,薛玉伦,等.成都市龙泉驿区癌痛现状及癌痛控制满意度调查[J].四川医学,2017,38(2):144-147.
[16]李琳.盐酸羟考酮缓释片初始滴定治疗老年癌痛的疗效观察[J].山西医药杂志,2017,46(6):684-686.
[17]姜本大.羟考酮对腹腔镜胆囊切除术患者拔管期应激反应、术后疼痛的影响分析[J].肝胆外科杂志,2017,25(1):46-49,80.
[18]贺冬林,冉凤鸣,臧爱华,等.奥施康定联合复方苦参注射液治疗中重度癌痛的疗效观察[J].数理医药学杂志,2014(2):203-205.
[19]Riley J,Eisenberg E,Müller-Schwefe G,et al. Oxycodone:a review of its use in the management of pain[J]. Curr Med Res Opin,2008,24(1):175-192.
[20]刘茗露,陈一伟,郭峰,等.不同途径应用盐酸羟考酮控释片治疗中重度癌性疼痛临床效果观察[J].中国误诊学杂志,2009,9(29):7057.
[21]张彦,蒋红凯,刘小珊,等.苦参碱诱导K562白血病细胞分化和凋亡的试验研究[J].癌症,2000,19(8):756-758.
[2]陈勇,黄红霞.加巴喷丁联合盐酸羟考酮缓释片对癌性神经痛患者疼痛介质的影响[J].中国实用神经疾病杂志,2017,20(4):116-118.
[3]胥秀,冯丹,贾罄竹,等.心智觉知干预模式对肺癌化疗患者生活质量和心理状况的影响[J].中华肺部疾病杂志(电子版),2017,10(1):50-54.
[4]张璐,朱敏,张慧,等. GCH1基因多态性与肺癌中晚期病人癌痛程度的相关性研究[J].中国疼痛医学杂志,2017,23(9):662-667.
[5]区妙兴,冼海兵,李巧云,等.医护合作式的电话随访在晚期肺癌患者疼痛管理中的应用[J].国际护理学杂志,2017,36(2):258-260.
[6]刘永叶,齐泽华,杨晓丹,等.奥施康定联合复方苦参注射液治疗胃癌晚期癌痛疗效观察[J].临床军医杂志,2017,45(1):13-15.
[7]郭一萌,杨静,严虹霞,等.复方苦参注射液辅助治疗肺癌的系统评价[J].中国医院用药评价与分析,2017,17(3):379-384.
[8]何静,李君,冯艺,等.利兹神经病理性症状和体征评分与疼痛强度的关系[J].中国疼痛医学杂志,2017,23(1):39-43.
[9]徐象威,朱佩祯,吕向群,等.临床药师参与大剂量阿片类药物癌痛会诊对患者疼痛及不良反应的分析[J].浙江医学,2017,39(3):208-211.
[10]胡夕春,王杰军,常建华,等.癌症疼痛诊疗上海专家共识(2017年版)[J].中国癌症杂志,2017,27(4):312-319.
[11]邓芸,卓兴峰,彭娟娟,等.盐酸羟考酮缓释片联合生物电刺激对神经病理性癌痛的治疗效果[J].川北医学院学报,2017,32(1):30-32.
[12]徐忠良,张辉,王德征,等. 2015年天津市户籍居民恶性肿瘤死亡及去死因期望寿命分析[J].中华流行病学杂志,2017,38(2):231-234.
[13]高崇荣.关于疼痛定义的商榷[J].中国疼痛医学杂志,2017,23(1):23-24.
[14]纪英,王倩,宋萍,等.自我效能干预对恶性肿瘤放化疗患者癌痛及生活质量的护理效果[J].中国医药导报,2017,14(8):171-174.
[15]唐丹,曾淑英,薛玉伦,等.成都市龙泉驿区癌痛现状及癌痛控制满意度调查[J].四川医学,2017,38(2):144-147.
[16]李琳.盐酸羟考酮缓释片初始滴定治疗老年癌痛的疗效观察[J].山西医药杂志,2017,46(6):684-686.
[17]姜本大.羟考酮对腹腔镜胆囊切除术患者拔管期应激反应、术后疼痛的影响分析[J].肝胆外科杂志,2017,25(1):46-49,80.
[18]贺冬林,冉凤鸣,臧爱华,等.奥施康定联合复方苦参注射液治疗中重度癌痛的疗效观察[J].数理医药学杂志,2014(2):203-205.
[19]Riley J,Eisenberg E,Müller-Schwefe G,et al. Oxycodone:a review of its use in the management of pain[J]. Curr Med Res Opin,2008,24(1):175-192.
[20]刘茗露,陈一伟,郭峰,等.不同途径应用盐酸羟考酮控释片治疗中重度癌性疼痛临床效果观察[J].中国误诊学杂志,2009,9(29):7057.
[21]张彦,蒋红凯,刘小珊,等.苦参碱诱导K562白血病细胞分化和凋亡的试验研究[J].癌症,2000,19(8):756-758.